major depressive disorder

Arrows hitting targets
Biotech

Gilgamesh links psychedelic to 94% remission rate in depression

The phase 2a data further the biotech’s attempt to follow the trail blazed by Johnson & Johnson.
Nick Paul Taylor May 27, 2025 11:00am
Cartoon of businessmen standing around a broken target

J&J ends phase 3 depression program over 'insufficient efficacy'

Mar 7, 2025 4:55am
A puzzle of the brain with one missing piece

Takeda regains home rights to depression drug from Neurocrine

Jan 28, 2025 4:16am
Baseball sitting in a glove against a dark background

After 3rd phase 3 strike, Relmada's depression drug is out

Dec 9, 2024 2:30pm
Close up of hallucinogenic mushrooms

Cybin psychedelic reduces depression severity after 12 months

Nov 18, 2024 12:57pm
failure crash no fail rocket cancelled end

Alto's midphase depression trial falls flat

Oct 23, 2024 4:47am